Monika Kellerer
Monika Kellerer is an expert in Endocrinology at Marienhospital Stuttgart (Germany). As of October 2026, ScienceLeadR ranks Monika Kellerer in the top 1% of experts worldwide for Diabetes Mellitus and Glucose Metabolism Disorders. Monika Kellerer has authored 123 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 490 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Cardiology - Internal Medicine - Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1996 - 2026
Number : 123
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes? PMID 42478869 — endocrinology, body mass index, diabetes mellitus, type 2, semaglutide | J Clin Endocrinol Metab | 2026 | 1 |
| Fundamentals of Diabetes Management. PMID 42190733 — diabetes mellitus, endocrine system diseases | Exp Clin Endocrinol Diabetes | 2026 | 0 |
| Once-Weekly Insulin Icodec: Safety Profile in Type 2 and Type 1 Diabetes Based on a Pooled Analysis of ONWARDS 1-6. PMID 42119975 — diabetes mellitus, injections, safety, insulin, medication errors, diabetes mellitus, type 1, endocrine system diseases, diabetes mellitus, type 2 | Endocr Pract | 2026 | 0 |
| Therapy of Type 2 Diabetes. PMID 42030955 — diabetes mellitus, therapeutics, diabetes mellitus, type 2 | Exp Clin Endocrinol Diabetes | 2026 | 0 |
| Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. PMID 41879791 — diabetes mellitus, lipoproteins, c-reactive protein, cardiovascular diseases, cholesterol, body weight, risk factors, therapeutics, heart disease risk factors, random allocation, triglycerides, pulse, diabetes mellitus, type 2, semaglutide | JAMA Cardiol | 2026 | 0 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map